AI 081
Alternative Names: AI-081Latest Information Update: 30 Jul 2025
At a glance
- Originator AcroImmune
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants; Vascular endothelial growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 22 Jul 2025 National Medical Products Administration (NMPA) China clears the phase II portion of the phase I/II BIPAVE-001 trial in Solid tumours
- 22 Jul 2025 Adverse events, pharmacokinetics and efficacy data from a phase I/II trial in Solid tumours released by OncoC4
- 22 Jul 2025 Pharmacodynamics data from a preclinical studies in Solid tumours released by AcroImmune